Supernus completes Indivior merger, secures $650M term loan, to trade under SUPN

Supernus Pharmaceuticals completed its merger with Indivior Pharmaceuticals on November 2, 2026, and will begin trading on the Nasdaq Global Market under the ticker SUPN on November 3. To fund the deal, Supernus entered into a $650 million senior secured term loan, borrowed in full at closing to fund the merger, refinance existing debt, cover transaction costs and support general corporate purposes.

Detected & updated continuously · Source: Nebula